Intradermal or intravenous administration typically requires 1–2 hours; patients often resume light activity same-day. Mild localised inflammation or fatigue within 24–48 hours is commonly reported. No extended downtime is expected. However, onset of any symptomatic benefit is gradual, unfolding over weeks rather than days. Immediate post-procedure monitoring protocols differ between clinics.
Approximately 10 registered trials are investigating stem cell and exosome therapies for menopause-related symptoms. A 2023 small-scale study of placental MSCs reported subjective improvement in hot flush frequency in 70% of participants over 12 weeks, though follow-up assessments remain limited. Exosome trials have focused on anti-inflammatory signalling rather than direct hormone replacement. No large multicentre randomised controlled trials have yet demonstrated safety or efficacy comparable to hormone therapy, and recruitment for new menopause-focused stem cell studies has stalled. Evidence remains preliminary and largely mechanistic.
我是候选人吗？ → · Menopause & Hormonal Health: full overview → · 更年期和激素健康成本 → · Cost →
由 StemCellAtlas 的编辑团队进行医学审查，与Dr Dmytro Stoyanov (Urologist · 31+ yrs clinical practice) 合作诊所 Stem Plus（索菲亚）的，根据 ISSCR、FDA 和 EMA 指南。 Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估